Sr. Clinical Development Director

Enveda is looking for a Clinical Development, Sr. Director to join our team! Remote | Full-Time | Monthly-travel | $225,000-$280,000 Everyone says they're reinventing drug discovery. We're proving it in the clinic. Enveda reads nature's chemistry with AI - the platform is built on it, and it finds new medicines ~4x faster than the industry standard. We reached unicorn status on a $150M Series D, our first medicines are now in clinical trials with a deep pipeline right behind them, and we're backed by Sanofi, Lux Capital, and Baillie Gifford, with former Pfizer R&D chief Mikael Dolsten on the board. The role As a Sr. Clinical Development Director at Enveda, you'll have two core roles: working with the VP of clinical development on asset strategy; and hands on ownership of key study activities. This is a leadership role without direct reports - you will be a subject matter expert for the asset, work closely with a range of team members (e.g. translational, clinical development, operations, statistics) to help drive efficiencies and successes of the programs. In the first year of this role, there are several key activities that you will be involved with or leading: helping review the data from Enveda’s first phase 2 study, while leading the expansion of this asset to new areas. This is a high impact opportunity where you'll influence the outcome of Enveda’s lead asset, ENV-294, while collaborating with some of the brightest minds in the industry. What you'll do Work closely with the VP of clinical development on strategic execution Lead on new protocol designs for specific new studies / indications, which may be in dermatology or beyond Assist in preparation and review of data packages and presentations Become an expert in ENV-294: mechanism and data, and ways to communicate this with investors and clinicians We're looking for Experience designing new clinical trials and associated supporting documents Leadership in interactions with other team members Strategic skills with regards asset expansion and pathway to registration and commercialization In depth data analysis and presentation